Evidence map›Paper›PMID 24550591›Full record

ArticleIndian journal of pharmacology

Comparison of efficacy, safety, and cost-effectiveness of various statins in dyslipidemic diabetic patients.

Abdulbari Bener, Muzeyyen Dogan, Lolwa Barakat, Abdulla O A A Al-Hamaq

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Author's reply: To PMID 24550591.Indian journal of pharmacology
    Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Abdulbari BenerDepartment of Medical Statistics and Epidemiology, Hamad Medical Corporation and, Departments of Public Health and Medical Education, Weill Cornell Medical College, Doha, Qatar.
Muzeyyen DoganDepartment of Chemistry, Faculty of Arts and Science, Yildiz Technical University, Istanbul, Turkey.
Lolwa BarakatClinical Pharmacy, Hamad General Hospital, Hamad Medical Corporation, Qatar.
Abdulla O A A Al-HamaqDiabetes & Health Education, Qatar Diabetic Association and Qatar Foundation, Doha, Qatar.
Hamad Medical Corporation · QAQatar Foundation · QAYıldız Technical University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimTo determine efficacy safety and the cost effectiveness, of the four most commonly prescribed statins (rosuvastatin, atorvastatin, pravastatin, and simvastatin) in the treatment of dyslipidemia among diabetic patients. MATERIALS AND

methodsThis is a cohort, observational, population-based study conducted at diabetic clinics of the Hamad Medical Hospital and Primary Health Care Centers (PHCC) over a period from January 2007 to September 2012. The study included 1,542 consecutive diabetes patients above 18 years of age diagnosed with dyslipidemia and prescribed any of the indicated statins. Laboratory investigations were taken from the Electronic Medical Records Database (EMR-viewer). The sociodemographic, height, weight, and physical activities were collected from Patient's Medical Records. Information about statin was extracted from the pharmacy drug database. The effective reductions in total cholesterol using rosuvastatin with atorvastatin, simvastatin, and pravastatin in achieving cholesterol goals and improving plasma lipids in dyslipidemic diabetic patients were measured. Serum lipid levels measured a 1 week before the treatment and at the end 2(nd) year.

resultsRosuvastatin (10 mg) was the most effective in reducing low-density lipoprotein cholesterol (LDL-C; 28.59%), followed by simvastatin 20 mg (16.7%), atorvastatin 20 mg (15.9%), and pravastatin 20 mg (11.59.3%). All statins were safe with respect to muscular and hepatic functions. Atorvastatin was the safest statin as it resulted in the least number of patients with microalbuminuria (10.92%) as compared to other statins. Treatment with rosuvastatin 10 mg was more effective in allowing patients to reach European and Adult Treatment Plan (ATP) III LDL-C goals as compared to other statins (P < 0.0001) and produced greater reductions in LDL-C, total cholesterol, and non-HDL-C, produced similar or greater reductions in triglycerides (TGs) and increased in HDL-C.

conclusionRosuvastatin 10 mg was the most effective statin in reducing serum lipids and total cholesterol in dyslipidemic diabetic patients.

Indexed as

Cost-Benefit AnalysisAdultCholesterol, LDLCohort StudiesDiabetes ComplicationsDyslipidemiasFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedSurveys and QuestionnairesCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsAtorvastatincost effectivedyslipidemic diabetic patientsefficacypravastatinrosuvastatinsafetysafety of statin use in dyslipidemic diabetic patientssimvastatin

Identifiers

PMID24550591
PMCPMC3912814
OpenAlexW2074262503

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.